McKesson account plan
Healthcare solutions and services
At a glance
McKesson is a U.S. healthcare services group built on drug distribution in North America: $403,430 million FY2026 revenue, 43,000+ employees.
McKesson, based in Irving, Texas, works with biopharma companies, care providers, pharmacies, manufacturers and governments; its core is wholesale drug distribution in the U.S. and Canada, surrounded by specialty and oncology provider services, prescription-access technology and medical-surgical supply. It says it distributes about 1/3 of pharmaceuticals in North America. In the fiscal year to March 31, 2026 (FY2026) revenues were $403,430 million (+12%), net income attributable to McKesson $4,762 million (+45%) and diluted EPS $38.38. It had more than 43,000 employees at March 31, 2026, about 38,000 of them in the U.S. and 5,000 in Canada. Brian S. Tyler has been CEO since April 2019 and Chairman since May 1, 2026.
Business units
North American Pharmaceutical
$336,652M FY2026 revenue, about 83% of group revenueDistributes branded, generic, specialty, biosimilar and OTC drugs in the U.S. and Canada to retail national accounts, community pharmacies and institutional providers, from a U.S. network of 27 distribution centers, and runs the Health Mart network of about 3,900 independent pharmacies and McKesson Canada. FY2026 operating profit was $3,658M (+24%); in Q1 FY2027 revenue was $86,773M (+5%) and operating profit $903M (+52%).
Oncology & Multispecialty
$48,423M FY2026 revenue, about 12% of group revenueSpecialty drug distribution, GPOs, infusion services and practice management for community specialists, supporting The U.S. Oncology Network (about 3,400 providers), PRISM Vision (80% owned), Sarah Cannon Research Institute (51% owned) and the Ontada data business. Revenue grew 31% in FY2026 and 33% in Q1 FY2027 to $14,222M, helped by the PRISM Vision and Core Ventures acquisitions.
Prescription Technology Solutions
$5,805M FY2026 revenue, about 1.4% of group revenueConnects patients, pharmacies, providers, PBMs, health plans and biopharma through electronic prior authorization, benefit insight and patient enrollment, plus third-party logistics, which is roughly 55% of its revenue. Connections reach over 50,000 pharmacies and over 650 biopharma brands; FY2026 operating profit was $1,044M with a 17.98% margin.
Medical-Surgical Solutions
$11,507M FY2026 revenue, about 3% of group revenueMedical-surgical supplies, lab equipment, pharmaceuticals and logistics for non-acute sites such as physician offices, surgery centers, nursing homes and home health, with more than 336,000 customers. It is being separated into a standalone company named Wellverse, expected to operate under that name from January 2027; Apollo Funds bought about 13% for about $1.25B on June 1, 2026.
Strategic priorities
- Grow oncology and multispecialty
- Expand the community specialty platform through physician recruitment, geographic expansion and tuck-in acquisitions; FY2027 guidance is O&M operating profit +13.5% to 17.5%, and the long-term target is +13% to 16%.
- Separate Medical-Surgical as Wellverse
- The business is "now operationally and legally separate" with its own capital structure (a $2.25 billion Term Loan B set up on June 9, 2026); an IPO is planned, with proceeds going principally to share repurchases.
- Expand biopharma access services
- Prescription Technology Solutions supported a record 3.4 million patients in the annual verification season and launched an integrated specialty access and affordability solution; it began supporting the CMS Medicare GLP-1 Bridge program in July 2026.
- Cost and operating-model programmes
- Three restructuring programmes run in parallel: enterprise technology operating-model initiatives ($650-700M, through FY2028), an RxTS efficiency programme ($200-250M, through FY2029) and new Corporate initiatives ($230-310M, through FY2028).
- Invest in AI and distribution automation
- The NAP outlook includes accelerated second-half FY2027 investments focused on growth and AI, with returns most likely from the beginning of 2028; a new Montreal distribution center uses AI and robots.
- Capital return
- About $5 billion of buybacks planned in FY2027 and free cash flow of about $4.5-4.9 billion; the quarterly dividend was raised to $0.94 from $0.82 in July 2026.
Latest results
In Q1 FY2027 (quarter to June 30, 2026) revenues rose 8% to $105,380M and adjusted EPS rose 20% to $9.93. GAAP diluted EPS fell to $5.15 from $6.25 because of a $293M charge to remeasure the Apollo minority interest in Medical-Surgical Solutions. Oncology & Multispecialty revenue grew 33% and adjusted segment operating profit 41%, while Medical-Surgical adjusted operating profit fell 20% on product mix and one-time administrative expenses. GLP-1 distribution revenue was $15 billion in the quarter (+24%). FY2027 adjusted EPS guidance was raised to $44.20-$45.00 (13% to 15% growth), with revenue growth of 5% to 9%.
Investments and deals
- Option Care Health stake
- On October 6, 2026 CD&R and McKesson agreed to acquire Option Care Health, the largest independent U.S. home and alternate-site infusion provider, at an enterprise value of about $5.8 billion; McKesson invests about $1.4 billion for about 49%, with closing expected in the first half of calendar 2027.
- Oncology and retina acquisitions
- Acquired 80% of PRISM Vision for $875M (April 1, 2025) and 70% of Core Ventures, the Florida Cancer Specialists services organisation, for $2.5B (June 2, 2025).
- Distribution centers
- Broke ground on a regional distribution center in Moore, Oklahoma that will raise throughput by 75%, after opening an AI- and robot-equipped Montreal distribution center.
- Exit from Europe
- Sold the Norwegian business on January 30, 2026 for $821M, completing the European exit.
- Capital spending
- FY2026 capex was $436M of property, plant and equipment plus $309M of capitalised software; Q1 FY2027 capex was $152M.
Challenges and risks
- Opioid litigation
- Many cases by states, counties and municipalities, with an estimated accrued liability of $5.7B at March 31, 2026.
- Drug-pricing policy
- IRA price negotiation (Part D changes from January 2028), the most-favored-nation executive order, the CMS bona fide service fee rule and 340B reform, on which Tyler says it is premature to estimate the impact.
- Customer concentration
- The ten largest customers were about 73% of FY2026 revenues, CVS Health alone about 24%, with the distribution partnership extended to June 2027.
- Thin distribution margins
- Gross profit margin was 3.61% in FY2026, and branded price decreases and brand-to-generic conversion weigh on distribution revenue.
- Separation and cyber risk
- The 10-K names execution and tax risk on the Med-Surg separation, cybersecurity incidents and AI adoption risks among its main risks.
What leadership says
“Our first quarter performance exceeded our expectations, highlighted by 20% growth in Adjusted Earnings per Diluted Share.”
“The raise in full year Adjusted Earnings per Diluted Share outlook reflects strong first quarter performance and sustainable operational momentum.”
“This investment represents an important opportunity that aligns with McKesson's long-term strategy to expand access and affordability to innovative therapies across the care continuum.”
“another great year of execution and disciplined portfolio actions”
Where a supplier can help
- Wellverse standalone set-up
- The Medical-Surgical separation into Wellverse, operating under that name from January 2027 with a planned IPO, creates needs for standalone systems, finance and branding.
- AI and automation tooling
- Accelerated second-half FY2027 investment in growth and AI, plus the Corporate initiatives on process enhancements and automation, open room for AI, data and workflow-automation suppliers.
- Distribution center build-out
- The new Moore, Oklahoma distribution center and the AI- and robot-equipped Montreal site point to demand for warehouse automation, robotics and logistics software.
- Oncology practice growth
- Growth in Oncology & Multispecialty through physician recruitment, geographic expansion and tuck-ins favours suppliers of practice software, recruiting and clinical data services.
- Cost-programme efficiency
- Three restructuring programmes totalling well over $1 billion of charges create openings for outsourcing, process and technology vendors that can show measurable savings.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like McKesson?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- McKesson Annual Report on Form 10-K, fiscal year ended March 31, 2026
- McKesson is a "diversified healthcare services leader" (roots in 1833, Irving, Texas) that partners with biopharma companies, care providers, pharmacies, manufacturers and governments; fiscal year ends March 31. More than 43,000 employees at March 31, 2026 (about 38,000 in the U.S., 5,000 in Canada).
- FY2026 revenues $403,430 million (+12%), gross profit $14,550 million (+9%, margin 3.61%), net income attributable to McKesson $4,762 million (+45%), diluted EPS $38.38 vs $25.72.
- Four reportable segments since Q2 FY2026: North American Pharmaceutical ($336,652M revenue, $3,658M operating profit), Oncology & Multispecialty ($48,423M, +31%), Prescription Technology Solutions ($5,805M, 17.98% margin) and Medical-Surgical Solutions ($11,507M).
- Portfolio reshaped: acquired 80% of PRISM Vision ($875M) and 70% of Core Ventures (Florida Cancer Specialists' services organisation, $2.5B); sold Norway (January 30, 2026, $821M); plans to separate Medical-Surgical Solutions into an independent company, with Apollo Funds taking about 13% for about $1.25B.
- Heavy customer concentration: ten largest customers about 73% of revenues; CVS Health about 24% (distribution partnership extended to June 2027); the next two at 11% and 10%.
- Cash: operating cash flow $6,155M; $4.8B of buybacks plus $381M dividends ($5.1B returned); capex $436M PP&E plus $309M capitalised software; new $5.0B buyback authorisation (total $7.7B) in April 2026.
- Cost programmes: enterprise-wide technology-operating-model initiatives ($650-700M total charges, done FY2028) and a new Prescription Technology Solutions efficiency programme ($200-250M, done FY2029); AI is in "early stages of exploring".
- Main risks: opioid litigation (accrued liability $5.7B), drug-pricing policy (IRA, most-favored-nation executive order, CMS bona fide service fee rule, 340B rebate models), cybersecurity, customer and supplier concentration, and execution of the Med-Surg separation.
- McKesson Quarterly Report on Form 10-Q, quarter ended June 30, 2026 (Q1 fiscal 2027)
- Q1 FY2027 (quarter to June 30, 2026): revenues $105,380M (+8%), gross profit $3,685M (+12%), income before taxes $1,308M (+24%).
- Net income attributable to McKesson fell to $614M (-22%) and diluted EPS to $5.15 from $6.25, because of a $293M charge to remeasure the Apollo minority interest in Medical-Surgical Solutions (plus $81M for Core Ventures).
- Segment revenues: North American Pharmaceutical $86,773M (+5%), Oncology & Multispecialty $14,222M (+33%), Prescription Technology Solutions $1,566M (+9%), Medical-Surgical Solutions $2,819M (+4%).
- Segment operating profit: NAP $903M (+52%), O&M $325M (+53%), RxTS $226M (-11%, restructuring), Med-Surg $122M (-45%, $45M separation charges).
- Med-Surg separation advanced: Apollo bought about 13% for about $1.25B on June 1, 2026; Med-Surg subsidiaries borrowed $3.2B net in secured term loans, used to repay an intercompany loan.
- New Corporate efficiency programme ($230-310M of charges, through FY2028) on top of the RxTS ($200-250M) and enterprise technology ($650-700M) programmes.
- Returned $2.6B to shareholders ($2.5B buybacks, $102M dividends); dividend raised to $0.94 from $0.82; remaining buyback authorisation $5.2B.
- McKesson Reports Fiscal 2027 First Quarter Results and Raises Full Year Adjusted EPS Guidance (earnings release)
- Q1 FY2027: revenues $105.4 billion (+8%); GAAP EPS $5.15 (down $1.10); Adjusted EPS $9.93 (+20%); Adjusted Earnings $1,183M (+14%).
- FY2027 Adjusted EPS guidance raised to $44.20-$45.00 (from $43.80-$44.60), 13% to 15% growth; no GAAP EPS forecast.
- Adjusted segment operating profit: North American Pharmaceutical $894M (+19%), Oncology & Multispecialty $405M (+41%), Prescription Technology Solutions $303M (+13%), Medical-Surgical Solutions $195M (-20%).
- Oncology & Multispecialty revenue $14.2 billion (+33%) including acquisitions; North American Pharmaceutical $86.8 billion (+5%).
- Medical-Surgical Solutions will become Wellverse (name unveiled August 5, 2026); Apollo bought about 13% for $1.25 billion on June 1, 2026; a $2.25 billion Term Loan B was set up on June 9, 2026.
- Dividend raised 15% to $0.94 a quarter (tenth consecutive year); $2.6 billion returned in the quarter.
- Leadership: Kenny Cheung is the new CFO; Ramesh Srinivasan became Chief Strategy Officer on August 1, 2026, replacing the retiring Thomas L. Rodgers.
- McKesson FQ1 2027 earnings call transcript (Brian Tyler, Kenny Cheung)
- Tyler: Q1 revenue +8% to $105 billion and adjusted EPS +20% to $9.93, "both results exceeding our expectations"; three segments grew operating profit by double digits; FY2027 adjusted EPS guidance raised to $44.20-$45.00.
- New CFO Kenny Cheung (joined in May) frames his job around a "strong say-do ratio" and disciplined capital allocation; FY2027 guide: revenue +5% to 9%, operating profit +9% to 13%, free cash flow $4.5-4.9 billion, about $5 billion of buybacks.
- Oncology & Multispecialty: more than 14,000 community providers served; The U.S. Oncology Network about 3,400 providers treating more than 2 million patients a year; PRISM Vision over 200 providers in 97 locations; SCRI took part in research behind 43 of the 52 adult oncology drugs approved by the FDA in 2025; new SCRI collaboration with Pfizer.
- O&M revenue +33% (about 24% excluding Core Ventures); Tyler says Florida Cancer Specialists is at "the high end of the guidance range"; growth now from physician recruitment, geographic expansion and AI-enabled capacity, not another deal of FCS scale.
- GLP-1 distribution revenue $15 billion in the quarter (+24%); McKesson began supporting the CMS Medicare GLP-1 Bridge program in July; 95% of prior authorisations get a determination within 30 minutes.
- AI: an enterprise AI training day at headquarters; a production-ready external data connection built in a single business day; accelerated second-half investment in growth and AI.
- Medical-Surgical becomes Wellverse, operating under that name from January 2027; new Moore, Oklahoma distribution center to raise throughput 75%.
- Policy: on 340B reform Tyler says it is premature to estimate impact; IRA Part D changes start January 2028; Cheung says more than 95% of branded drugs are fee-for-service.
- McKesson FQ4 2026 earnings call transcript (Brian Tyler, Britt Vitalone)
- FY2026 (to March 2026): revenues $403 billion (+12%), adjusted operating profit $6.5 billion (+15%), adjusted EPS $39.11 (+18%), operating cash flow $6.2 billion, $5.1 billion returned; return on invested capital 34%.
- FY2027 initial guide: adjusted EPS $43.80-$44.60 (12% to 14%); long-term targets reaffirmed: adjusted EPS +13% to 16%, segment operating profit NAP +5% to 8%, O&M +13% to 16%, RxTS +10% to 13%.
- Medical-Surgical separation: business now operationally and legally separate; Apollo's 13% stake values it at about $13 billion of enterprise value; an IPO is planned.
- Governance: Tyler elected Chairman effective May 1; Dominic Caruso Lead Independent Director; CFO Britt Vitalone retiring after 20 years.
- U.S. Oncology Network added more than 570 providers in FY2026; Ambient Scribe used by more than 1,900 providers; PRISM Vision providers up about 20%.
- RxTS supported a record 3.4 million patients in annual verifications; launched an integrated specialty access and affordability solution.
- Distribution: new AI- and robot-equipped Montreal distribution center; AI planning system cut working capital; McKesson distributes about 1/3 of pharmaceuticals in North America; GLP-1 revenues $53 billion in FY2026 (+27%).
- CD&R and McKesson Corporation Sign Agreement to Acquire Option Care Health (press release, Form 8-K exhibit 99.1)
- October 6, 2026: CD&R and McKesson agreed to acquire Option Care Health (Nasdaq: OPCH), the largest independent U.S. home and alternate-site infusion provider, for $32.05 per share, an enterprise value of about $5.8 billion.
- CD&R takes about 51%; McKesson invests about $1.4 billion for about 49%, accounted for by the equity method; a framework allows McKesson to later acquire CD&R's stake.
- Premium about 37% to the October 5, 2026 close; closing expected in the first half of calendar 2027, subject to Option Care stockholder and regulatory approvals.
- Option Care has over 8,000 team members including more than 5,000 clinicians, in all 50 states, and remains a separate company with its own management.
- Brian Tyler: the investment "aligns with McKesson's long-term strategy to expand access and affordability to innovative therapies across the care continuum", in lower-cost community settings.
- Rationale: growth in specialty, rare and orphan therapies and alternate-site infusion; McKesson brings specialty pharmaceutical expertise.
Questions about McKesson
What does McKesson do?
McKesson is a healthcare services company whose core is wholesale drug distribution in the U.S. and Canada. It also runs oncology and multispecialty provider services, prescription-access technology for biopharma and a medical-surgical supply business being separated as Wellverse.
What is McKesson's revenue?
Revenues were $403,430 million in the fiscal year to March 31, 2026, up 12%. In Q1 FY2027 (to June 30, 2026) revenues were $105,380M, up 8%.
How many employees does McKesson have?
More than 43,000 at March 31, 2026: about 38,000 in the U.S. and 5,000 in Canada.
Who leads McKesson?
Brian S. Tyler is Chair and CEO (CEO since April 2019). Kenny Cheung joined as CFO in May 2026, and Ramesh Srinivasan became Chief Strategy Officer on August 1, 2026.
What is McKesson's strategy?
Grow oncology and multispecialty and biopharma access services, separate Medical-Surgical as Wellverse, invest in AI and distribution automation, and return cash through buybacks and dividends.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)